Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company, has announced it will report its second quarter 2024 financial results after market close on Wednesday, August 14, 2024. The company, which focuses on developing therapies using its lipid nanocrystal (LNC) platform delivery technology, will host an investment community conference call and webcast at 4:30 p.m. Eastern time on the same day to discuss the financial results and provide a business update. Interested parties can participate in the call by dialing (866) 682-6100 (Toll-Free) or (862) 298-0702 (Toll). The webcast will be available on the IR Calendar page of the Matinas website and will be archived for six months.
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), una compagnia biofarmaceutica in fase clinica, ha annunciato che diffonderà i suoi risultati finanziari del secondo trimestre 2024 dopo la chiusura del mercato, mercoledì 14 agosto 2024. L'azienda, che si concentra sullo sviluppo di terapie utilizzando la sua tecnologia di consegna a base di nanocristalli lipidici (LNC), ospiterà una conference call con la comunità degli investitori e webcast alle 16:30 ora orientale dello stesso giorno per discutere i risultati finanziari e fornire un aggiornamento aziendale. Le parti interessate possono partecipare alla call componendo il numero (866) 682-6100 (Gratuito) o (862) 298-0702 (A pagamento). Il webcast sarà disponibile nella pagina del Calendario IR del sito web di Matinas e sarà archiviato per sei mesi.
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), una empresa biofarmacéutica en fase clínica, ha anunciado que reportará sus resultados financieros del segundo trimestre de 2024 después del cierre del mercado el miércoles 14 de agosto de 2024. La compañía, que se enfoca en desarrollar terapias utilizando su tecnología de entrega de nanocristales lipídicos (LNC), llevará a cabo una conferencia telefónica y webcast para la comunidad de inversores a las 4:30 p.m. hora del Este ese mismo día para discutir los resultados financieros y proporcionar una actualización empresarial. Las partes interesadas pueden participar en la llamada marcando el (866) 682-6100 (Gratis) o (862) 298-0702 (De pago). El webcast estará disponible en la página del Calendario IR del sitio web de Matinas y estará archivado durante seis meses.
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB)는 임상 단계의 생명공학 회사로서 2024년 2분기 재무 결과를 2024년 8월 14일 수요일 시장 폐장 후 발표할 것이라고 발표했습니다. 이 회사는 리피드 나노크리스탈(LNC) 플랫폼 전달 기술을 사용하여 치료제를 개발하는 데 초점을 맞추고 있으며, 같은 날 오후 4:30 동부 시간에 재무 결과를 논의하고 사업 업데이트를 제공하기 위해 투자자 커뮤니티를 위한 전화 회의 및 웹캐스트를 개최할 예정입니다. 관심 있는 분들은 (866) 682-6100 (무료) 또는 (862) 298-0702 (유료)로 전화하여 참여할 수 있습니다. 웹캐스트는 Matinas 웹사이트의 IR 캘린더 페이지에서 이용할 수 있으며 6개월 동안 아카이브됩니다.
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), une entreprise biopharmaceutique en phase clinique, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 après la fermeture du marché le mercredi 14 août 2024. L'entreprise, qui se concentre sur le développement de thérapies utilisant sa technologie de livraison de nanocristaux lipidiques (LNC), organisera une conférence téléphonique et un webcast pour la communauté des investisseurs à 16h30 heure de l'Est le même jour pour discuter des résultats financiers et fournir une mise à jour sur l'entreprise. Les parties intéressées peuvent participer à l'appel en composant le (866) 682-6100 (numéro gratuit) ou le (862) 298-0702 (numéro payant). Le webcast sera disponible sur la page Calendar IR du site Matinas et sera archivé pendant six mois.
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat bekannt gegeben, dass es seine finanziellen Ergebnisse für das zweite Quartal 2024 nach Marktschluss am Mittwoch, den 14. August 2024 bekannt geben wird. Das Unternehmen, das sich auf die Entwicklung von Therapien mit seiner Lipid-Nanokristall (LNC) Plattform-Liefertechnologie konzentriert, wird am selben Tag um 16:30 Uhr Eastern Time eine Konferenzschaltung und ein Webcast für die Investorencommunity veranstalten, um die finanziellen Ergebnisse zu diskutieren und ein Unternehmensupdate bereitzustellen. Interessierte Parteien können an dem Anruf teilnehmen, indem sie (866) 682-6100 (gebührenfrei) oder (862) 298-0702 (gebührenpflichtig) wählen. Der Webcast wird auf der IR-Kalenderseite der Matinas-Website verfügbar sein und für sechs Monate archiviert werden.
- None.
- None.
BEDMINSTER, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report second quarter 2024 financial results after market close on Wednesday, August 14, 2024. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update that day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
To participate in the call, please dial (866) 682-6100 (Toll-Free) or (862) 298-0702 (Toll). The webcast will be available on the IR Calendar page of the Matinas website and will be archived for six months.
About Matinas BioPharma
Matinas BioPharma is a biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology.
Matinas’ lead LNC-based therapy is MAT2203, an oral formulation of the broad-spectrum antifungal drug amphotericin B, which although highly potent, can be associated with significant toxicity. Matinas’ LNC platform provides oral delivery of amphotericin B without the significant nephrotoxicity otherwise associated with IV-delivered formulations. Combining comparable fungicidal activity with targeted delivery results in a lower risk of toxicity and potentially creates the ideal antifungal agent for the treatment of invasive fungal infections. MAT2203 was successfully evaluated in the completed Phase 2 EnACT study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 will be further evaluated in a single Phase 3 registration trial (the “ORALTO” trial) as an oral step-down monotherapy following treatment with AmBisome® (liposomal amphotericin B) compared with the standard of care in patients with invasive aspergillosis who have limited treatment options.
In addition to MAT2203, preclinical and clinical data have demonstrated that this novel technology can potentially provide solutions to many challenges of achieving safe and effective intracellular delivery of both small molecules and larger, more complex molecular cargos including small oligonucleotides such as ASOs and siRNA. The combination of its unique mechanism of action and flexibility with routes of administration (including oral) positions Matinas’ LNC technology to potentially become a preferred next-generation orally available intracellular drug delivery platform. For more information, please visit www.matinasbiopharma.com.
Forward-looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to our business activities, our strategy and plans, the future development of our product candidates, including MAT2203, the Company’s ability to identify and pursue development, licensing and partnership opportunities for our products, including MAT2203, or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to continue as a going concern, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company’s intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company’s products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma’s product candidates are all in a development stage and are not available for sale or use.
Investor Contact
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100
FAQ
When will Matinas BioPharma (MTNB) report its Q2 2024 financial results?
What time is Matinas BioPharma's (MTNB) Q2 2024 earnings call scheduled for?
How can investors participate in Matinas BioPharma's (MTNB) Q2 2024 earnings call?
What is Matinas BioPharma's (MTNB) main focus as a company?
